$EXPO

EXPONENT INC

No enriched coverage for $EXPO in the last 7 days.

No SEC Form 4 filings for $EXPO in the last 30 days.

Med

UBS Group Cuts Exponent (NASDAQ:EXPO) Price Target to $75.00

UBS Group has reduced its price target for Exponent (NASDAQ:EXPO) from $85.00 to $75.00, maintaining a "neutral" rating on the stock. This adjustment comes despite Exponent reporting better-than-expected Q1 earnings with EPS of $0.59 and revenue of $166.3 million, and the company increasing its quarterly dividend and share buyback authorization. Insiders have been net sellers, and the stock is currently trading down, with a P/E ratio around 31.

Earnings call transcript: Exponent Q1 2026 sees stock rise post-earnings

Exponent Inc. reported Q1 2026 earnings, with EPS of $0.57 exceeding forecasts and revenue of $144.47 million meeting expectations. The company's stock rose by 1.07% in aftermarket trading, reflecting strong performance driven by AI integration in consumer electronics and increased demand from energy and utility sectors. Exponent's CEO highlighted a strategic focus on innovation, while new President John Pye and CFO Eric Anderson were introduced, signaling a leadership evolution to capitalize on developing market trends.

JPMorgan Chase & Co. Sells 157,457 Shares of Exponent, Inc. $EXPO

JPMorgan Chase & Co. reduced its stake in Exponent, Inc. (NASDAQ:EXPO) by 24.7% in the third quarter, selling over 157,000 shares, though still holding 480,624 shares valued at $33.39 million. While other institutional investors made significant purchases, company insiders, including the CEO and a VP, sold a combined 9,583 shares. Exponent, which analysts rate a "Moderate Buy" with a $92.50 average target, recently beat earnings estimates and increased its quarterly dividend.